These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 32090621)

  • 1. The 18th FRAME Annual Lecture, October 2019: Human
    Rodriguez B
    Altern Lab Anim; 2019; 47(5-6):221-227. PubMed ID: 32090621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New approaches in pharmacology: numerical modelling and simulation].
    Boissel JP; Cucherat M; Nony P; Dronne MA; Kassaï B; Chabaud S
    Therapie; 2005; 60(1):1-15. PubMed ID: 15929468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-silico human electro-mechanical ventricular modelling and simulation for drug-induced pro-arrhythmia and inotropic risk assessment.
    Margara F; Wang ZJ; Levrero-Florencio F; Santiago A; Vázquez M; Bueno-Orovio A; Rodriguez B
    Prog Biophys Mol Biol; 2021 Jan; 159():58-74. PubMed ID: 32710902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human
    Passini E; Britton OJ; Lu HR; Rohrbacher J; Hermans AN; Gallacher DJ; Greig RJH; Bueno-Orovio A; Rodriguez B
    Front Physiol; 2017; 8():668. PubMed ID: 28955244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico pharmacology for drug discovery: applications to targets and beyond.
    Ekins S; Mestres J; Testa B
    Br J Pharmacol; 2007 Sep; 152(1):21-37. PubMed ID: 17549046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico clinical trials: concepts and early adoptions.
    Pappalardo F; Russo G; Tshinanu FM; Viceconti M
    Brief Bioinform; 2019 Sep; 20(5):1699-1708. PubMed ID: 29868882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.
    Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A
    Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting.
    Kloft C; Poggesi I
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1599-604. PubMed ID: 20969486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report from the EPAA workshop: in vitro ADME in safety testing used by EPAA industry sectors.
    Schroeder K; Bremm KD; Alépée N; Bessems JG; Blaauboer B; Boehn SN; Burek C; Coecke S; Gombau L; Hewitt NJ; Heylings J; Huwyler J; Jaeger M; Jagelavicius M; Jarrett N; Ketelslegers H; Kocina I; Koester J; Kreysa J; Note R; Poth A; Radtke M; Rogiers V; Scheel J; Schulz T; Steinkellner H; Toeroek M; Whelan M; Winkler P; Diembeck W
    Toxicol In Vitro; 2011 Apr; 25(3):589-604. PubMed ID: 21167275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Pharmacology Society: 5th annual meeting.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2006 Jan; 5(1):181-5. PubMed ID: 16370966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial simulation in drug development.
    Girard P; Cucherat M; Guez D;
    Therapie; 2004; 59(3):287-95, 297-304. PubMed ID: 15559184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations.
    Corrias A; Jie X; Romero L; Bishop MJ; Bernabeu M; Pueyo E; Rodriguez B
    Philos Trans A Math Phys Eng Sci; 2010 Jun; 368(1921):3001-25. PubMed ID: 20478918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches to assessing cardiac safety--proceedings of a workshop: regulators, industry and academia discuss the future of in silico cardiac modelling to predict the proarrhythmic safety of drugs.
    Fletcher K; Shah RR; Thomas A; Tobin F; Rodriguez B; Mirams GR; Saiz J; Noble D
    Drug Saf; 2011 May; 34(5):439-43. PubMed ID: 21513366
    [No Abstract]   [Full Text] [Related]  

  • 20. 2011 Annual Meeting of the Safety Pharmacology Society: an overview.
    Cavero I
    Expert Opin Drug Saf; 2012 Mar; 11(2):341-53. PubMed ID: 22339583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.